GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Enterprise Value

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Enterprise Value : $21.41 Mil (As of May. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Clarus Therapeutics Holdings's Enterprise Value is $21.41 Mil. Clarus Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $-22.27 Mil. Therefore, Clarus Therapeutics Holdings's EV-to-EBIT ratio for today is -0.96.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Clarus Therapeutics Holdings's Enterprise Value is $21.41 Mil. Clarus Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-22.25 Mil. Therefore, Clarus Therapeutics Holdings's EV-to-EBITDA ratio for today is -0.96.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Clarus Therapeutics Holdings's Enterprise Value is $21.41 Mil. Clarus Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 was $16.91 Mil. Therefore, Clarus Therapeutics Holdings's EV-to-Revenue ratio for today is 1.27.


Clarus Therapeutics Holdings Enterprise Value Historical Data

The historical data trend for Clarus Therapeutics Holdings's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Enterprise Value Chart

Clarus Therapeutics Holdings Annual Data
Trend Dec20 Dec21
Enterprise Value
- 74.24

Clarus Therapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Enterprise Value Get a 7-Day Free Trial - 134.18 74.24 66.23 41.21

Competitive Comparison of Clarus Therapeutics Holdings's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Clarus Therapeutics Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarus Therapeutics Holdings's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clarus Therapeutics Holdings's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Clarus Therapeutics Holdings's Enterprise Value falls into.



Clarus Therapeutics Holdings Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Clarus Therapeutics Holdings's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as

Clarus Therapeutics Holdings's Enterprise Value for the quarter that ended in Jun. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarus Therapeutics Holdings  (OTCPK:CRXTQ) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Clarus Therapeutics Holdings's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=21.405/-22.272
=-0.96

Clarus Therapeutics Holdings's current Enterprise Value is $21.41 Mil.
Clarus Therapeutics Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.27 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Clarus Therapeutics Holdings's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=21.405/-22.245
=-0.96

Clarus Therapeutics Holdings's current Enterprise Value is $21.41 Mil.
Clarus Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.25 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Clarus Therapeutics Holdings's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=21.405/16.909
=1.27

Clarus Therapeutics Holdings's current Enterprise Value is $21.41 Mil.
Clarus Therapeutics Holdings's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarus Therapeutics Holdings Enterprise Value Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Executives
Thomas Mcnerney & Partners Lp 10 percent owner 45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr director C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory director C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley director, officer: Chief Executive Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson officer: Chief Financial Officer 1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger officer: Chief Commercial Officer CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne officer: Chief Administrative Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd 10 percent owner DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p. 10 percent owner 45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Headlines

From GuruFocus